Breast-Cancer-Portal

As the challenges of individualized medicine grow, particularly in the realm of precision-guided therapy, the importance of using appropriate biomarkers is becoming increasingly evident. The collaboration between pathologists, oncologists, molecular biologists, and human geneticists is now more crucial than ever in planning the most precise and effective therapy possible.

QuIP has taken on the mission of assisting pathologists in Germany and Europe by helping them optimize their diagnostic results and supporting them in all relevant professional and organizational quality assurance activities. The Breast-Cancer-Portal is designed to serve as a resource for pathologists, as well as specialists in other disciplines and oncologists, providing guidance at the critical interface between biomarker testing and therapy.

The Breast-Cancer-Portal provides two biomarker-based treatment algorithms - one for Early Breast Cancer and one for Advanced/Metastatic Breast Cancer. These algorithms are grounded in current medical guidelines and the latest scientific evidence, with detailed explanations of the underlying tests. The portal presents information on biomarkers, tests, analyses, and treatment options in a compact format, enabling pathologists and oncology physicians to quickly access relevant information and understand the therapeutic implications.

Additional information is available through the German Arbeitsgemeinschaft Gynäkologische Onkologie (AGO Recommendations). The S3 Breast Cancer Guideline can be accessed on the website of the German Association of the Scientific Medical Societies (AWMF).

The portal is available in both German and English.

The scientific literature supporting the content of the Breast-Cancer-Portal is cited for each respective algorithm passage and is compiled as a list under a separate 'References' tab. Additionally, references are cited and identified throughout the continuous texts. The listed research literature reflects the most current processing status of the portal editors and is ­continuously updated or supplemented as necessary.

Please note: The information on the Breast-Cancer-Portal is compiled to the best of our knowledge. However, we cannot guarantee the completeness, accuracy and/or timeliness of the information. This is particular true for content that does not originate from us but is linked to third-party sources. For the most current and detailed information on the products, please refer to the respective technical documentation.

Additionally, it is important to note that different pathologists may reach varying conclusions when diagnosing images. In our reference sections, we always specify the exact data on which each evaluation is based. The interpretation and evaluation of your own specimens remain your sole responsibility. Should you have any questions, please do not hesitate to contact us at any time.

Due to data protection regulations in Germany, QuIP is unable to publicly share the Breast-Cancer-Portal and its direct website link. Only the introductory information is visible on the portal's start page, with all other content restricted to medical professionals.

Registered QuIP users can automatically access the Breast-Cancer-Portal by logging in on the QuIP homepage. Additionally, physicians with DocCheck access can also enter the Breast-Cancer-Portal. Other interested parties who do not have a QuIP account or DocCheck access can request entry by sending an e-mail to QuIP. An access code will be provided after verifying the requestor's eligibility.

QuIP is supported by AstraZeneca, Lilly, Menarini Stemline, MSD Sharp & Dohme, Pierre Fabre and Sanofi.

Status: August 2024